FDA considers adding a dozen peptides to its bulk drug compounding list RAPS FDA Peptide Reclassification 2026: What It Means for Providers Peptides in 2026, What the FDA Review Means Olympia Pharmaceuticals After being placed into FDA Category 2 in 2023, several widely discussed peptides faced restricted pathways for regulated compounding. This shift pushed demand toward unregulated markets and created significant uncertainty across the FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner Orthopedic Use of BPC 157 Sports Med Review